Pfizer releases more positive data for COVID-19 oral antiviral

Dec 14, 2021 - 11:53 AM
COVID19 Web Sized

Pfizer today announced additional phase 2/3 clinical trial data for its COVID-19 oral antiviral treatment, indicating the pill’s high degree of effectiveness in reducing high-risk patients’ risks of hospitalization or death from SARS-CoV-2 infection. Pfizer said that, among high-risk patients, the antiviral reduced risk of hospitalization or death by 89% when taken within three days of symptoms’ onset, with a similar effectiveness — 88% — when administered within five days of symptoms. Interim results from an ongoing study of standard-risk adults indicate a 70% reduction in hospitalizations, with zero deaths. Pfizer also released in vitro data indicating that the drug would maintain its effectiveness against omicron and future SARS-CoV-2 variants. 

Related News Articles

Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
ACIP recommends patients consult their provider for COVID-19 vaccine
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
RFK Jr. says CDC will no longer recommend COVID-19 vaccine for healthy children, pregnant women
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
FDA to limit COVID-19 vaccine to people over 65, others at high risk for serious illness
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
Senate Finance Committee advances RFK Jr. nomination for HHS secretary
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…